Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Gilliland

Showing results (141-150 of 182) with videos related to

Pageof 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2010
Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617FWindy Berkofsky-Fessler, Monica Buzzai, Marianne K-H Kim, et al.
Cancer Cell|June 15, 2010
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cellsAnn Mullally, Steven W Lane, Brian Ball, et al.
Blood|March 16, 2007
A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemiaTing-lei Gu, Thomas Mercher, Jeffrey W Tyner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3Thomas Fischer, Richard M Stone, Daniel J Deangelo, et al.
The Journal of Experimental Medicine|February 1, 2006
Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutationsHanna S Radomska, Daniela S Bassères, Rui Zheng, et al.
Translational Oncology|January 17, 2013
Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT InhibitorsWeisheng Zhang, Brian B Haines, Clay Efferson, et al.
Plos Medicine|July 13, 2006
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasiaYana Pikman, Benjamin H Lee, Thomas Mercher, et al.
Cell Stem Cell|June 6, 2009
Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesisInga Hofmann, Elizabeth H Stover, Dana E Cullen, et al.
Blood|May 10, 2007
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panelAyalew Tefferi, Juergen Thiele, Attilio Orazi, et al.
Cancer Research|April 21, 2011
Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemiasBrynn T Kvinlaug, Wai-In Chan, Lars Bullinger, et al.
Pageof 19

Showing results (141-150 of 182) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2010
Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617FWindy Berkofsky-Fessler, Monica Buzzai, Marianne K-H Kim, et al.
Cancer Cell|June 15, 2010
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cellsAnn Mullally, Steven W Lane, Brian Ball, et al.
Blood|March 16, 2007
A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemiaTing-lei Gu, Thomas Mercher, Jeffrey W Tyner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3Thomas Fischer, Richard M Stone, Daniel J Deangelo, et al.
The Journal of Experimental Medicine|February 1, 2006
Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutationsHanna S Radomska, Daniela S Bassères, Rui Zheng, et al.
Translational Oncology|January 17, 2013
Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT InhibitorsWeisheng Zhang, Brian B Haines, Clay Efferson, et al.
Plos Medicine|July 13, 2006
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasiaYana Pikman, Benjamin H Lee, Thomas Mercher, et al.
Cell Stem Cell|June 6, 2009
Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesisInga Hofmann, Elizabeth H Stover, Dana E Cullen, et al.
Blood|May 10, 2007
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panelAyalew Tefferi, Juergen Thiele, Attilio Orazi, et al.
Cancer Research|April 21, 2011
Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemiasBrynn T Kvinlaug, Wai-In Chan, Lars Bullinger, et al.
Pageof 19